v3.26.3
Deconsolidation Of Lokahi And Discontinued Operations
9 Months Ended
Sep. 30, 2026
Discontinued Operations and Disposal Groups [Abstract]  
DECONSOLIDATION OF LOKAHI AND DISCONTINUED OPERATIONS

NOTE 3 — DECONSOLIDATION OF LOKAHI AND DISCONTINUED OPERATIONS

 

As described in Note 1, 51% of the equity of Lokahi was transferred to RXRR Capital Partners under the Settlement Agreement, and on July 14, 2026 Lokahi became a wholly owned subsidiary of Glucotrack. The Company no longer controls Lokahi and deconsolidated it in accordance with ASC 810-10-40. The Company elected to measure the deconsolidation using Lokahi’s June 30, 2026 balances. The gain on deconsolidation was measured as the fair value of the consideration received less the carrying amount of Lokahi’s net liabilities derecognized, as follows:

 

    Amount  
Fair value of Glucotrack common stock received (37,884 shares)   $ 15,813  
Fair value of Glucotrack Series A preferred stock to be received (2,269,100 shares as converted)     947,122  
Total fair value of consideration received     962,935  
Carrying amount of Lokahi net liabilities derecognized     6,840,718  
Gain on deconsolidation of Lokahi   $ 7,803,653  

 

The Glucotrack securities were measured using Glucotrack’s closing price of $6.261 per share on July 14, 2026, or $0.4174 per share before Glucotrack’s 1-for-15 reverse stock split effective August 31, 2026. Share amounts above are stated before that reverse stock split. The Series A preferred stock, which had not been issued to the Company as of September 30, 2026, is measured on an as-converted basis. Lokahi’s net liabilities derecognized comprised total assets of $2,497,274, including cash of $53,186, and total liabilities of $9,337,992, including notes payable of $5,000,000, accrued interest of $1,240,350, notes payable — related party of $500,100 and operating lease liabilities of $161,396. The gain is included in income (loss) from discontinued operations.

 

Lokahi conducted the Company’s BioBusiness segment, which was the Company’s entire biopharmaceutical business and its only operating business before the acquisition of MindWave on December 1, 2025. The disposal represents a strategic shift that has a major effect on the Company’s operations and financial results, and the results of Lokahi are presented as discontinued operations for all periods presented. General corporate overhead has not been allocated to discontinued operations. Interest on Lokahi’s notes payable, which were obligations of Lokahi, is included in discontinued operations. The comparative 2025 periods are presented on the basis used in the segment disclosure in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, under which all operating expenses before December 1, 2025 were attributed to the BioBusiness; the change in fair value of the warrant liability, interest income and interest expense for those periods remain in continuing operations.

 

The results of discontinued operations were as follows:

 

    Three months ended
September 30,
2026
    Nine months ended
September 30,
2026
    Three months ended
September 30,
2025
    Nine months ended
September 30,
2025
 
Research and development   $ —     $ 1,860,886     $ 619,693     $ 1,271,477  
General and administrative     (8,675 )     5,370,140       1,224,546       3,601,034  
Interest expense     —       2,261,232       —       —  
Interest income     —       (21,757 )     —       —  
Income (loss) from operations of Lokahi     8,675       (9,470,501 )     (1,844,239 )     (4,872,511 )
Gain on deconsolidation of Lokahi     7,803,653       7,803,653       —       —  
Income (loss) from discontinued operations   $ 7,812,328     $ (1,666,848 )   $ (1,844,239 )   $ (4,872,511 )

 

Lokahi’s results for the six months ended June 30, 2026 include $1,281,090 of legal and consulting fees funded under the Settlement Agreement (see Note 7) and interest on Lokahi’s notes payable (see Note 8). General and administrative expense of discontinued operations for the three months ended September 30, 2026 consists of the reversal of stock-based compensation on unvested options forfeited by employees and consultants of Lokahi (see Note 10).

 

The assets and liabilities of discontinued operations as of December 31, 2025 were as follows. There were no assets or liabilities of discontinued operations as of September 30, 2026.

 

    December 31,
2025
 
Cash and cash equivalents   $ 1,492,054  
Short-term investments     2,000,000  
Prepaid expenses     2,298,704  
Current assets of discontinued operations     5,790,758  
Long-term prepaid expenses     75,485  
Property and equipment, net     51,626  
Operating lease right-of-use asset, net     187,395  
Noncurrent assets of discontinued operations     314,506  
Total assets of discontinued operations   $ 6,105,264  
Accounts payable and accrued expenses   $ 247,884  
Accrued interest     27,952  
Notes payable — related party     500,100  
Operating lease liability, current     39,578  
Current liabilities of discontinued operations     815,514  
Operating lease liability, net of current portion (noncurrent liabilities of discontinued operations)     129,454  
Total liabilities of discontinued operations   $ 944,968  

 

The Company presents the cash flows of discontinued operations combined with those of continuing operations in the condensed consolidated statements of cash flows. Cash of Lokahi of $53,186 derecognized on deconsolidation is presented within investing activities. Depreciation, amortization, capital expenditures and significant noncash items of the discontinued operations were as follows:

 

    Nine months ended September 30,
2026
    Nine months ended September 30,
2025
 
Depreciation of property and equipment   $ 9,091     $ 1,721  
Amortization of operating lease right-of-use asset     31,232       —  
Stock-based compensation     219,376       1,934,727  
Reversal of stock-based compensation on forfeited options     (8,675 )     —  
Accretion of debt discount — Lokahi notes payable     955,000       —  
Non-cash interest accrued — Lokahi notes payable     1,212,398       —  
Gain on deconsolidation of Lokahi     (7,803,653 )     —  
Capital expenditures     9,394       35,909  
Non-cash investing activity — Glucotrack securities received     962,935       —  

 

After the disposal, the Company’s continuing involvement with Lokahi consists of its investment in Glucotrack (Note 5), the Apitox royalty and revenue participation rights assigned by FreeT (Note 1), the San Diego office lease, which remains in the Company’s name (Note 13), and stock options of the Company held by former employees and consultants of Lokahi (Note 10).

 

License agreements. The Company’s license and supply arrangements with Apimeds, Inc. (Korea), a related party, relating to APITOX were part of the BioBusiness and are included in discontinued operations through the deconsolidation of Lokahi. No milestone payments became due and no royalty obligations were incurred during the three and nine months ended September 30, 2026 or 2025. After the disposal, the Company’s rights relating to Apitox consist of the royalty and revenue participation rights assigned by FreeT described in Note 1. Refer to the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 for a description of the material terms of the license agreements.